RANK pathway in cancer: underlying resistance and therapeutic approaches

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis

Background:

• Metastatic cancers, particularly osteolytic bone metastases, severely reduce quality of life in advanced cancer patients.
• The interaction between circulating tumor cells and the bone microenvironment drives breast cancer progression.
• There is a critical need for novel therapeutic strategies for breast cancer patients with bone metastases.

Approach:

• This review provides a comprehensive overview of the Receptor Activator of Nuclear Factor kappa-B Ligand (RANKL) pathway in cancer.
• We discuss the intricate role of RANK signaling within the tumor microenvironment.
• Potential therapeutic approaches targeting this pathway are explored.

Key Points:

• RANKL-RANK signaling is a crucial component of the cancer-bone microenvironment interaction.
• Disrupting the RANKL-RANK pathway can inhibit cancer cell progression and metastasis.
• The tumor microenvironment plays a significant role in mediating cancer cell survival and growth.

Conclusions:

• The RANK pathway represents a viable therapeutic target for managing breast cancer bone metastases.
• Targeting RANKL-RANK interactions holds potential for developing novel anti-metastasis treatments.
• Further research into RANK signaling is essential for advancing cancer therapy.